ESMO Immuno-Oncology & Advanced Therapies Congress 2026: What to Know About December's London Gathering

What this article covers
- Key Dates and Location
- The congress runs December 14–16, 2026, at the Queen Elizabeth II Centre in London, United Kingdom. It is organized by ESMO, one of the two largest medical oncology societies in the world (alongside the American Society of Clinical Oncology), and is held both onsite and online.
- What the Event Covers
- Unlike ESMO's flagship Congress, which spans all of oncology, this meeting is narrowly built around immune-based cancer treatment. According to event listings, the program is designed to cover "the entire spectrum from basic science to translational research and clinical development" in immuno-oncology.
- Who Attends
- ESMO describes the meeting's audience as specialists in cancer immunotherapy — medical oncologists, translational researchers, and industry and regulatory stakeholders — rather than a general-interest or patient-facing event. It draws a more specialized crowd than ESMO's October Congress, reflecting how much the immuno-oncology field has grown into its own distinct subspecialty over the past decade.
- Why It Matters for Patients and Families
- Conferences like this one are where incremental, sometimes consequential, shifts in immunotherapy research first surface publicly — new combination data, early biomarker findings, or updated guidance on managing side effects. None of that becomes a treatment recommendation the moment it is presented; results shown at a congress are typically preliminary, unreviewed by regulators, and often represent single studies rather than established practice.
- Bottom Line
- The ESMO Immuno-Oncology & Advanced Therapies Congress 2026 is a real, confirmed, specialist-focused meeting — December 14–16 in London — that offers a useful window into where cancer immunotherapy research is actively moving, from bispecific antibodies to cellular therapies for solid tumors. As with any conference, what gets presented there is research in progress, not a finished or approved treatment, and readers should treat early data presented in December as a signal to watch rather than a guide to what is currently available or proven.
In mid-December 2026, the European Society for Medical Oncology (ESMO) will convene its annual Immuno-Oncology & Advanced Therapies Congress in London — a focused, three-day meeting built entirely around cancer immunotherapy, from checkpoint inhibitors and bispecific antibodies to cellular therapies for solid tumors. This article previews what the congress covers, who typically attends, and why patients and families following immunotherapy research may want to pay attention to what comes out of it, while being clear about what a conference preview can and cannot tell readers about any individual treatment's effectiveness or availability.
Key Dates and Location
The congress runs December 14–16, 2026, at the Queen Elizabeth II Centre in London, United Kingdom. It is organized by ESMO, one of the two largest medical oncology societies in the world (alongside the American Society of Clinical Oncology), and is held both onsite and online. This continues an annual tradition — the 2025 edition was also held in London, at the same venue — making the Immuno-Oncology Congress ESMO's dedicated, year-end counterpart to its much larger general Congress (held in October 2026 in Madrid).
What the Event Covers
Unlike ESMO's flagship Congress, which spans all of oncology, this meeting is narrowly built around immune-based cancer treatment. According to event listings, the program is designed to cover "the entire spectrum from basic science to translational research and clinical development" in immuno-oncology. Based on the congress's recurring structure and this year's confirmed programming, expect sessions on:
- Checkpoint inhibitors and emerging combination strategies
- Bispecific antibodies, a rapidly expanding drug class in solid and blood cancers
- Cellular therapies for solid tumors — an area where progress has lagged behind blood cancers
- Biomarkers that predict both clinical benefit and toxicity risk in precision immunotherapy
- Managing immune-related side effects (toxicities) from immunotherapy
- Newer frontiers, including neoantigen-based vaccines, myeloid cells in the tumor microenvironment, single-cell and spatial biology tools, and applications of AI in immuno-oncology drug development
A notable addition for 2026: ESMO and the Society for Immunotherapy of Cancer (SITC) — the two leading immuno-oncology societies in Europe and the US, respectively — are jointly running an educational "Primer" session on December 14, taught by SITC experts, aimed at grounding attendees in foundational immuno-oncology concepts before the main scientific sessions begin.
Who Attends
ESMO describes the meeting's audience as specialists in cancer immunotherapy — medical oncologists, translational researchers, and industry and regulatory stakeholders — rather than a general-interest or patient-facing event. It draws a more specialized crowd than ESMO's October Congress, reflecting how much the immuno-oncology field has grown into its own distinct subspecialty over the past decade.
Why It Matters for Patients and Families
Conferences like this one are where incremental, sometimes consequential, shifts in immunotherapy research first surface publicly — new combination data, early biomarker findings, or updated guidance on managing side effects. None of that becomes a treatment recommendation the moment it is presented; results shown at a congress are typically preliminary, unreviewed by regulators, and often represent single studies rather than established practice. Patients and caregivers following a specific cancer type may still find it useful to track which research groups and drug classes are presenting, since that often signals where a field is heading well before any approval follows.
Bottom Line
The ESMO Immuno-Oncology & Advanced Therapies Congress 2026 is a real, confirmed, specialist-focused meeting — December 14–16 in London — that offers a useful window into where cancer immunotherapy research is actively moving, from bispecific antibodies to cellular therapies for solid tumors. As with any conference, what gets presented there is research in progress, not a finished or approved treatment, and readers should treat early data presented in December as a signal to watch rather than a guide to what is currently available or proven.
Key Questions Answered
- When and where is the ESMO Immuno-Oncology & Advanced Therapies Congress 2026?
- December 14–16, 2026, at the Queen Elizabeth II Centre in London, held both onsite and online.
- What topics will the congress cover?
- Checkpoint inhibitors and combinations, bispecific antibodies, cellular therapies for solid tumors, predictive biomarkers, immune-related toxicity management, neoantigen vaccines, spatial biology and AI in drug development.
- Does data presented at the congress mean a treatment is proven or available?
- No. Congress results are typically preliminary, unreviewed by regulators and often from single studies; they are signals to watch, not treatment recommendations.
Sources
- ESMO Immuno-Oncology Congress 2026 — UroToday Calendar, 2026 — https://www.urotoday.com/calendar-events/esmo-immuno-oncology-congress-2026.html
- ESMO Immuno-Oncology & Advanced Therapies Congress 2026 — LMU Klinikum Pharmakologie Event Listing, 2026 — https://auth.lmu-klinikum.de/pharmakologie/p-esmo-immuno-oncology-amp-advanced-therapies-congress-2026-p/65d66eb8053a35d6
- General Event Details — IQVIA CVS Solutions (EMT-26-10868), 2026 — https://cvs.solutions.iqvia.com/event/detail/EMT-26-10868
- SITC and ESMO Announce Joint Primer Program for December 2026 — OncoDaily, 2026 — https://oncodaily.com/societies/sitc-609903
- ESMO Immuno-Oncology Congress 2026 — Medflixs Agenda Listing, 2026 — https://www.medflixs.com/en/agenda/esmo-immuno-oncology-congress-2026/show
- Queen Elizabeth II Centre, London — ESMO Immuno-Oncology Congress Venue Listing — OncoDaily, 2026 — https://oncodaily.com/venue/queen-elizabeth-ii-centre-in-london-united-kingdom/
- ESMO Congress 2026 — HealthManagement.org, 2026 — https://healthmanagement.org/c/hospital/Event/esmo-congress-2026
Related Articles
- Research & Industry
ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage
The world's largest clinical oncology meeting returns to Chicago in June 2027, with cell therapy, immunotherapy, and antibody-drug conjugate research expected to headline the scientific program once again.
- Research & Industry
AACR IO 2027: What to Expect From the Immuno-Oncology Conference Coming to Los Angeles
AACR IO 2027 meets in Los Angeles February 28–March 3, focusing on cancer vaccines, engineered T cells and early clinical data—not confirmed treatment advances.
- Research & Industry
CAR-T Therapy for Autoimmune Disease in France: What's Actually Happening
France hosts investigational CAR-T trials for severe lupus, but September 2026 safety pauses underscore serious risks and the absence of an approved autoimmune therapy.